🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial
  2. ETOPOSIDE, PACLITAXEL, IFOSFAMIDE, CISPLATIN, CARBOPLATIN

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial
  3. EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled pen, EVENITY 105 mg solution for injection in pre-filled pen

    Amgen

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial
  4. EVEROLIMUS

    Novartis Pharmaceuticals

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial
  5. EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

    Pfizer Australia Pty Ltd

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial
  6. EVO100

    Evofem Biosciences

    Sexually Transmitted Diseases

    phase 3 small molecule completed

    1 trial
  7. EVO100

    Evofem Biosciences

    Chlamydia Trachomatis Infection

    phase 3 small molecule completed

    1 trial
  8. EXPAREL 13.3Mg/mL Suspension for Injection

    Pacira Ireland Limited

    Bunion

    phase 3 small molecule terminated

    1 trial
  9. Ebglyss 250 mg solution for injection in pre-filled syringe, Placebo, Ebglyss 250 mg solution for injection in pre-filled pen

    Almirall, S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial
  10. Efgartigimod, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial
  11. Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial
  12. Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

    Genzyme Europe B.V.

    Gaucher's disease type I; Gaucher's disease type III

    phase 3 small molecule active

    1 trial
  13. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial
  14. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial
  15. Empagliflozin 10 mg

    United Therapeutics Europe Ltd

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial
  16. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial
  17. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial
  18. Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection

    Janssen-Cilag International N.V.

    Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial
  19. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    phase 3 small molecule active

    1 trial
  20. Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.

    Lacuna Pharma Pty Ltd

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial
  21. Enema transplant of fecal microbiota, Placebo Enema transplant of fecal microbiota

    Pari Pharma GmbH

    Adult patients with ulcerative colitis diagnosed for at least 3 months

    phase 3 small molecule active

    1 trial
  22. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen

    Takeda

    Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial
  23. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial
  24. Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources